Studies

AIMS: Acquired hypothalamic obesity (aHO) following craniopharyngioma (CP) is a challenging condition with limited therapeutic options. This study aimed to assess the real-world effectiveness and safety of GLP-1 RAs in this population. MATERIALS AND…

Microglial activation driven by NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome signaling exacerbates Alzheimer's disease (AD) pathology through enhanced neuroinflammation and amyloid beta (Aβ) accumulation. Semaglutide (SEM) ha…

OBJECTIVES: Interest in incretin therapy for type 1 diabetes is increasing, but data are lacking regarding patient-reported outcomes and personal experience among those using this drug. METHODS: This work is an analysis from a double-blind, randomize…

AIMS: To analyse prescribing trends in antidiabetic agents stratified by background characteristics among individuals with type 2 diabetes. MATERIALS AND METHODS: This retrospective study used a large-scale database between 2015 and 2024 in Japan. Ad…

Dysfunctional epicardial adiposity is a risk factor for coronary artery disease (CAD). Its genesis is associated with an upregulation of fatty acid binding protein 4 (FABP4) levels, which might exert paracrine inflammatory and atherogenic mechanisms…

The existing literature on the effects of semaglutide in people with HIV (PWH) and diabetes mellitus remains limited. In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observation…

AIMS: Real-world studies of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates t…

Chronic kidney disease poses a major global health burden and is one of the most common complications of type 2 diabetes. Drug trials have demonstrated that treatments, including sodium-glucose cotransporter-2 inhibitors, a glucagon-like peptide-1 re…

IMPORTANCE: Metabolic dysfunction-associated steatotic liver disease (MASLD) includes a range of liver conditions, progressing from isolated steatosis (characterized by fat accumulation in the liver without inflammation) to metabolic dysfunction-asso…

BACKGROUND: Evidence suggests that glucagon-like peptide 1 receptor agonists (GLP-1RAs) might have pro-cognitive effects. No prior study has evaluated the efficacy and safety of a GLP-1RA for the treatment of cognitive dysfunction in adults with majo…

The management of diabetes relies heavily on macromolecular biologics, which are predominantly administered via subcutaneous injection. However, its invasiveness compromises patient compliance and leads to injection-related complications. Among all t…

The NLRP3 inflammasome is a key innate immune sensor that orchestrates inflammatory responses to diverse stress signals, including metabolic danger cues. Dysregulated NLRP3 activation has been implicated in chronic diseases such as type 2 diabetes, a…

AIM: A retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide. METHODS: Glucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide b…

OBJECTIVE: This study summarizes the evidence on the clinical effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in adults with idiopathic intracranial hypertension (IIH). BACKGROUND: IIH is characterized by elevated intracranial pressu…

INTRODUCTION: Once-weekly semaglutide has proven to be a safe and effective treatment for type 2 diabetes; however, clinical trial data on Asian populations are limited, warranting real-world data (RWD). In this study we assessed the effectiveness an…